- Home
- SGC vs NTHI Comparison
SGC vs NTHI Comparison
Compare SGC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- NTHI
- Stock Information
- Founded
- SGC 1920
- NTHI 2008
- Country
- SGC United States
- NTHI United States
- Employees
- SGC N/A
- NTHI N/A
- Industry
- SGC Apparel
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- NTHI Health Care
- Exchange
- SGC Nasdaq
- NTHI Nasdaq
- Market Cap
- SGC 163.3M
- NTHI 142.5M
- IPO Year
- SGC N/A
- NTHI N/A
- Fundamental
- Price
- SGC $9.99
- NTHI $7.37
- Analyst Decision
- SGC Strong Buy
- NTHI
- Analyst Count
- SGC 3
- NTHI 0
- Target Price
- SGC $17.00
- NTHI N/A
- AVG Volume (30 Days)
- SGC 48.1K
- NTHI 89.8K
- Earning Date
- SGC 05-08-2025
- NTHI 01-01-0001
- Dividend Yield
- SGC 5.62%
- NTHI N/A
- EPS Growth
- SGC N/A
- NTHI N/A
- EPS
- SGC 0.45
- NTHI N/A
- Revenue
- SGC $563,931,000.00
- NTHI $79,990.00
- Revenue This Year
- SGC $1.02
- NTHI N/A
- Revenue Next Year
- SGC $3.98
- NTHI N/A
- P/E Ratio
- SGC $22.17
- NTHI N/A
- Revenue Growth
- SGC 2.28
- NTHI 13.52
- 52 Week Low
- SGC $9.11
- NTHI $4.11
- 52 Week High
- SGC $21.80
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- SGC 46.88
- NTHI N/A
- Support Level
- SGC $9.69
- NTHI N/A
- Resistance Level
- SGC $9.96
- NTHI N/A
- Average True Range (ATR)
- SGC 0.32
- NTHI 0.00
- MACD
- SGC 0.03
- NTHI 0.00
- Stochastic Oscillator
- SGC 41.30
- NTHI 0.00
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").